Theravance Biopharma, Inc. (FRA:0TB)
Germany · Delayed Price · Currency is EUR 17.10
+0.10 (0.59%)
At close: Nov 28, 2025
Theravance Biopharma Company Description
Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States.
It offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD).
Its late-stage investigational once-daily norepinephrine reuptake inhibitor, Ampreloxetine is in the development for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA).
It has a strategic collaboration agreement with Viatris Inc. for the development and commercialization of revefenacin, including YUPELRI.
Theravance Biopharma, Inc. was incorporated in 2013 and is based in South San Francisco, California.
Theravance Biopharma, Inc.
| Country | Cayman Islands |
| Founded | 2013 |
| Industry | Pharmaceutical Preparations |
| Employees | 97 |
| CEO | Rick Winningham |
Contact Details
Address: 901 Gateway Boulevard South San Francisco, 94080 United States | |
| Phone | 650 808 6000 |
| Website | theravance.com |
Stock Details
| Ticker Symbol | 0TB |
| Exchange | Frankfurt Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Rick Winningham | Chief Executive Officer |
| Aziz Sawaf | Chief Financial Officer |